fbpx
Skip to main content
4/28/2015

CDF Presents Patient-Focused Celiac Drug Development Survey Data to FDA

On May 11, 2015, the Food and Drug Administration (FDA) will conduct a public meeting on Functional GI Disorders Patient-Focused Drug Development. Celiac Disease Foundation was requested by the FDA to provide commentary about the impact of celiac disease on patients’ daily lives, the types of treatment benefit that matter most to patients, and patients’ perspectives on the adequacy of the available therapies.

Continue Reading
4/8/2015

Will There Ever Be a Drug for Celiac Disease?

New drugs on the research horizon could spare people with celiac the pain of accidentally eating pizza or pasta. Even with the best intentions, living gluten-free is much easier said than done. It was almost impossible to tell which packaged “gluten-free” foods lived up to their claims until late last year when the U.S. Food and Drug Administration (FDA) began enforcing gluten-free labeling guidelines. And it's hard to guarantee you won’t accidentally consume gluten at a restaurant or on an occasion, such as a well-meaning relative’s dinner party.

Continue Reading
3/5/2015

The Gluten-Free Allergy-Free Marketplace Launches at Celiac.org

Underscoring its role as a leader in online tools for the gluten-free community, Celiac Disease Foundation (CDF) today launched the Gluten-Free Allergy-Free Marketplace, a new retail destination hosted on celiac.org. Featured at celiac.org/marketplace, the Marketplace showcases products and services from companies that care about the gluten-free and allergy-free community, and have made a deep commitment to supporting CDF’s mission of diagnosis, treatment, and a cure for celiac disease.

Continue Reading
2/26/2015

CDF Announces New Members to Board of Directors

Celiac Disease Foundation, the nation’s leading voluntary health organization for celiac disease, announces the appointment of four new members of its Board of Directors for the 2015-2017 term. Joining the Board of Director are Emily Luxford, Jody Morris, Jordan Ramer, and Jim Watson.

Continue Reading